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Abstract
Notch hyperactivation dominates T-cell acute lymphoblastic leukemia development, but the mechanisms underlying “pre-
leukemic” cell dissemination are still unclear. Here we describe how deregulated Notch3 signaling enhances CXCR4 cell-
surface expression and migratory ability of CD4+CD8+ thymocytes, possibly contributing to “pre-leukemic” cell propagation,
early in disease progression. In transgenic mice overexpressing the constitutively active Notch3 intracellular domain, we
detect the progressive increase in circulating blood and bone marrow of CD4+CD8+ cells, characterized by high and
combined surface expression of Notch3 and CXCR4. We report for the first time that transplantation of such CD4+CD8+ cells
reveals their competence in infiltrating spleen and bone marrow of immunocompromised recipient mice. We also show that
CXCR4 surface expression is central to the migratory ability of CD4+CD8+ cells and such an expression is regulated by
Notch3 through β-arrestin in human leukemia cells. De novo, we propose that hyperactive Notch3 signaling by boosting
CXCR4-dependent migration promotes anomalous egression of CD4+CD8+ cells from the thymus in early leukemia stages.
In fact, in vivo CXCR4 antagonism prevents bone marrow colonization by such CD4+CD8+ cells in young Notch3 transgenic
mice. Therefore, our data suggest that combined therapies precociously counteracting intrathymic Notch3/CXCR4 crosstalk
may prevent dissemination of “pre-leukemic” CD4+CD8+ cells, by a “thymus-autonomous” mechanism.
Introduction
Malignant transformation of T-cell progenitors is causative
of T-cell acute lymphoblastic leukemia (T-ALL). T-ALL
accounts for 15% of pediatric and 25% of adult ALL cases,
very frequently bearing somatic gain-of-function gene
mutations in Notch1, as well as overexpression of Notch3
[1–3]. Moreover, Notch3 gene activating mutations have
been recently reported in T-ALL [4]. Notch receptors reg-
ulate T-cell fate choices, dominating early steps of thymo-
cyte differentiation [5, 6]. Additionally, thymocyte turnover
is regulated by natural cell competition, between “young”
bone marrow (BM)-derived and “old” thymus-resident
progenitors, whose impairment enables T-ALL progres-
sion via pre-malignant stages [7]. A major role is also
played by the interaction between leukemia and non-
leukemia cells in the microenvironment, probably dictating
the survival of leukemia initiating cells.
Chemokines drive T-cell development through a
gradient-dependent directional migration. Secreted by stro-
mal and epithelial cells, chemokines mediate physiological
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and pathological processes, essentially related to cell hom-
ing and migration [8]. In adult thymus, T-cell precursors
development requires CXCL12, also termed stromal
derived factor-1 (SDF-1), which by binding to the G protein
coupled receptor (GPCR), CXCR4, and through multiple
divergent pathways, leads to chemotaxis, survival, and
proliferation [8]. Through the cortex and medulla, GPCRs
guide immature thymocytes to the appropriate micro-
environment for specific developmental stages: CD4−CD8−
Double Negative (DN)1–4 to CD4+CD8+ Double Positive
(DP) stages and CD4+ or CD8+ Single Positive (SP),
respectively [9]. Moreover, SDF-1/CXCR4 axis is linked to
mature SP thymocytes egress from the thymus [10, 11].
CXCR4, highly expressed since DN2 to the DP stage [12,
13], drives normal intrathymic T-cell development [14].
During β-selection, the SDF-1/CXCR4 axis cooperates with
preTCR to allow Notch-dependent differentiation of DN3 to
DP thymocytes. Moreover, CXCR4 regulates preTCR-
dependent survival signals and maturation of thymocytes
during β-selection [15]. This early selection is under the
control of two Notch receptors, Notch1 mainly driving DN2
to DN3, while Notch3 governing DN3 to DP thymocyte
transitions [16, 6]. Both preTCR and CXCR4 signals con-
verge on Erk phosphorylation, regulating SDF-1-induced
chemotaxis of DN3 thymocytes [17, 14].
We previously demonstrated the oncogenic potential of
Notch3 in transgenic (tg) mice, overexpressing the con-
stitutively active intracellular domain of Notch3 (N3-IC) in
immature thymocytes, which develop an aggressive T-cell
ALL, recapitulating most of human T-ALL features. Four-
week-old N3-ICtg mice display early precursor deregulation,
by expanding the DN3 stage and increasing total thymic
cellularity [18]. At 12 weeks, thymus depletion, splenome-
galy, lymph nodes enlargement, and BM colonization by
lymphoblastic cell population occur. Phenotypic similarities
between the infiltrating lymphoma cells and the thymocytes
of younger mice suggested an immature T-cell propagation
[18]. Notably, a prominent feature in Notch-induced T-ALL
mouse models is the circulation of CD4+CD8+ T-cells [19,
20]. Moreover, disrupted natural cell competition in the
thymus may enable progression to leukemia by dissemina-
tion of pre-T-ALL CD4lo/+/CD8+ cells [7].
Here, we study anomalous CD4+CD8+ T-cells propa-
gation in Notch3-IC-induced T-ALL, by detecting atypical
DP T-cells outside the thymus at early and late T-ALL
stages. Notably, our results highlight that the high and
combined expression of CXCR4 and Notch3 defines “pre-
leukemic” DP-cells, precociously detected inside the thy-
mus, and then in circulating blood and BM. Newly, by
experiments of in vivo cell-transfer, we delineate the bio-
logical properties of CD4+CD8+Notch3+CXCR4+ thymo-
cytes that are fit to infiltrate peripheral organs. Notably, in
young transgenic N3-ICtg mice, the in vivo administration
of the CXCR4 antagonist, AMD3100, can drastically
reduce the infiltration of CD4+CD8+Notch3+CXCR4+ T-
cells into BM. Interestingly, by ex vivo and in vitro
experiments, we demonstrate that Notch3 modulates
CXCR4 cell-surface expression through a β-arrestin-medi-
ated mechanism, both in N3-ICtg mice-derived cells and in
the human TALL-1 cell line, known to harbor Notch3
activating mutations [21].
Overall, our data suggest that in Notch3-induced T-ALL
leukemia, high Notch3 and CXCR4 co-expression marks
“pre-leukemic” DP thymocytes and allows their egression and
propagation outside the thymus. This finally gives them
access to the blood stream and BM and favors T-ALL
progression.
Results
High CXCR4 cell-surface expression correlates with
enhanced migration of N3-ICtg DP thymocytes
Aberrant preT/T-cell development, Protein Kinase C θ-
dependent constitutive activation of NF-κB, persistent
expression of pTα/preTCR chain, and a failure of CD25
downmodulation beyond the DP stage characterize N3-ICtg
mice [18, 2, 22, 23].
SDF-1/CXCR4 axis-mediated DN/DP transition and its
suggested relevance in T-ALLs [14] prompted us to analyze
CXCR4 expression in abnormally represented DP T-cells in
N3-ICtg mice.
First, we observed a higher CXCR4 cell-surface
expression in transgenic DP thymocytes at the single cell
level (Fig. 1a), as highlighted by the significant difference
in the CXCR4 mean fluorescence intensity (MFI) between
wild-type (WT) and N3-ICtg DP-gated thymocytes of 6–8-
week-old mice. Increased CXCR4 expression seems to not
be transcriptionally regulated (Fig. 1b). Moreover, in DP
thymocytes of N3-ICtg as well as in WT mice, SDF-1
mRNA is undetectable (data not shown). Our data propose a
leukemic cell-autonomous mechanism, excluding SDF-1
autocrine production, as previously reported [24, 25]. In
addition, we observed a greatly decreased expression of
SDF-1 mRNA in N3-ICtg as opposed to WT whole thymus
(Fig. 1c).
SDF-1/CXCR4 axis-mediated chemotaxis regulates thy-
mocyte maturation by directing DP T-cells into the cortex
[26] and retaining them there. In our model, enhanced cell-
surface expression correlates to CXCR4 function. In fact, in
response to SDF-1, N3-ICtg DP thymocyte migration
increases more than WT DP cell migration and does so in a
dose-dependent manner (Fig. 1d).
Conceivably, transgenic DP thymocytes, with higher
CXCR4 surface expression, are more responsive to SDF-1,
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whose reduced expression in the N3-ICtg thymus micro-
environment (Fig. 1c) and decreased retaining function may
deregulate their progressive maturation into the thymic
cortex and increase their responsivity to external stimuli.
Notch3+highCXCR4+highDP T-cells competitively
increase in N3-ICtg thymus
Relative to WT, DP T-cell percentages of 3– and 6–8-week-
old transgenic thymi are unchanged (Fig. 2a, b), while
slightly decreased in 12–14-week-old mice (Figure S1A).
High CXCR4 (Fig. 1a) and the persistent Notch3 cell-
surface expression (Figure S1B), prompted us to evaluate
Notch3 and CXCR4 combined expression in CD4+CD8+
thymocytes at different ages.
In 3-week-old thymi, DP-gated thymocytes display a
higher percentage of Notch3+CXCR4+ cells in N3-ICtg
versus WT mice (35.6% ± 8.7% versus 6.0% ± 3.1%) (Fig.
2a, right panels), thus indicating their increase before full-
blown disease. CD4+CD8+Notch3+CXCR4+ thymocytes
of 6–8-week-old N3-ICtg mice strongly increase (66.5% ±
11.3%) within the DP population and stain more brightly
(Fig. 2b). Notably, the very few Notch3+CXCR4-DP thy-
mocytes in N3-ICtg mice suggest that the Notch3 signal
forces DP thymocytes to become Notch3+highCXCR4+high.
This is sustained by the strong increase in their absolute
numbers in N3-ICtg as opposed to in WT mice (Fig. 2d).
We then compared the absolute numbers of different subsets
of DP cells, by normalizing the number of DP cells bearing
only one or both the receptors (CXCR4 and/or Notch3) to
DP thymocyte total number. Respectively, Notch3−CXCR4
+ or Notch3+CXCR4+ versus total DP thymocytes, at dif-
ferent ages, from younger (3-week old) to older mice
(12–14-week old) have been analyzed. With respect to WT,
3-week-old transgenic thymus displays a significant
expansion of CD4+CD8+Notch3+CXCR4+ thymocytes,
further increasing in 6–8 and persisting in 12–14-week-old
mice (Fig. 2c). At each age, N3-ICtg thymus is progres-
sively more populated by CD4+CD8+Notch3+highCXCR4
+high, when compared to WT thymus. Conversely, CD4
+CD8+Notch3−CXCR4+high T-cell number decreases with
age in N3-ICtg thymus (Fig. 2c).
Fig. 1 Enhanced CXCR4 cell-
surface expression and
migratory ability in N3-ICtg
thymocytes. a surface CXCR4
mean fluorescence intensity
(MFI) on DP-gated thymocytes
of WT (n= 4) and N3-ICtg (n
= 5) mice; b CXCR4 mRNA
expression in DP thymocytes of
WT (n= 3) and N3-ICtg (n= 3)
mice; c SDF-1 mRNA
expression in whole thymi of
WT (n= 3) and N3-ICtg (n= 3)
mice; dMigration of WT (n= 3)
and N3-ICtg (n= 3) DP
thymocytes in response to
(20–200 ng/ml) SDF-1,
evaluated as fold increase of DP
migrating thymocytes
percentages in SDF-1 stimulated
versus unstimulated thymocytes
(CTRL). Unrelated ligand, SLC.
Each experiment was performed
with 6–8-week-old mice.
Results represent mean ± SD.
(*p < 0.05; **p<0.01; ***p <
0.001; ns, not significant;
Student’s t-test)
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Clearly, hyperactive Notch3 induces an overcoming DP
subset, which brightly expresses Notch3 and CXCR4
receptors.
Anomalous Notch3+CXCR4+DP T-cells are detected
early in circulating blood of N3-ICtg
Infiltration of CD4+CD8+ T-cells in peripheral lymphoid
organs has already been demonstrated in preclinical models
of Notch-induced T-ALL [18, 27, 20]. Moreover, Pin1
deletion prevents leukemia progression by reducing Notch3
expression and blocking the expansion/invasiveness of cir-
culating CD4+CD8+ T-cells in N3-ICtg blood [21].
Given the competitive increase of Notch3+highCXCR4
+highDP thymocytes in 3-week-old N3-ICtg mice (Fig. 2a)
and CXCR4-mediated SP cell egress, we evaluated the
immunophenotype of atypical CD4+CD8+ cells in
circulating blood (Fig. 3). Before the full-blown disease, the
blood of 3-week-old N3-ICtg mice is virtually devoid of DP
T-cells (0.5% ± 0,1%), as compared to WT mice (0.3% ±
0.2%) (Fig. 3a, left panels). Consequently, Notch3+CXCR4
+DP T-cells are virtually undetectable (Fig. 3a, right
panels). Conversely, by 6–8 weeks (Fig. 3b, upper panels),
we find CD4+CD8+ (4.0% ± 1.0%) in N3-ICtg blood,
mostly composed of Notch3+highCXCR4+highDP cells
(74,4% ± 15,0%), recalling the specific Notch3+highCXCR4
+highDP transgenic thymocytes (Fig. 2b). At 12–14 weeks,
when the disease progresses (Fig. 3b, lower panels), DP T-
cells percentage increases in N3-ICtg blood (8,0% ± 4,0%).
Within this population of DP T-cells, Notch3+CXCR4+
(23,0% ± 4,6%) are progressively replaced by Notch3
−/lowCXCR4− T-cells. Consequently, CD4+CD8+Notch3
+highCXCR4+high cells portray the early circulating DP T-
cells in the blood of our T-ALL model.
Fig. 2 High Notch3+CXCR4+ cell-surface co-expression characterizes
N3-ICtg DP thymocytes. a Left: thymocytes subset distribution with
average DP percentage ± SD. Right: DP-gated thymocytes with aver-
age percentage ± SD of Notch3+CXCR4+DP cells. WT (n= 3) and
N3-ICtg (n= 4) mice. b Left: thymocytes subset distribution with
average DP percentage ± SD; right: DP-gated thymocytes with average
percentage ± SD of Notch3+CXCR4+DP cells. WT (n= 7) and N3-
ICtg (n= 9) mice. c Absolute numbers of Notch3+CXCR4+ and/or
Notch3-CXCR4+DP normalized to total DP thymocytes values.
Student’s t-test between WT and N3-ICtg at each age; symbols § and *
indicate Notch3−CXCR4+ and Notch3+CXCR4+, respectively. For
each corresponding age, WT (n= 4) and N3-ICtg (n= 5) mice were
used. One-way ANOVA and Tukey’s post-test (left side) among dif-
ferent aged N3-ICtg (ns, not significant, **p < 0.01; ***p<0.001;
****p < 0.0001; §§§§p < 0.0001; §§p < 0.01). d CD4+CD8+Notch3
+highCXCR4+high absolute numbers in N3-ICtg (n= 3) versus WT (n
= 3) mice (*p < 0.05; **p < 0.01). See also Figure S1
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In support of deregulated CXCR4 expression, transgenic
CD8+ thymocytes show a decreased percentage of CXCR4
+ cells and a reduced SDF-1-induced migration when
compared to CD8+ WT thymocytes (Figure S2A and B). It
is possible that Notch3 activation impairs thymocyte
development beyond the DP stage by favouring precocious
exit of DP thymocytes from the thymus, finally affecting
CD8+ T-cells maturation.
Based on the ratio between CD4+CD8+Notch3+CXCR4
+ and CD4+CD8+Notch3-CXCR4+ T-cell percentage, we
observed in 6–8-week-old N3-ICtg blood stream the max-
imum expansion of circulating Notch3+CXCR4+DP T-cells
(Fig. 3c), which overcome Notch3−CXCR4+DP T-cells. At
12–14 weeks, with the disease fully developed, the ratio of
Notch3+CXCR4+ versus Notch3-CXCR4+ DP subsets
within the total DP population is greatly decreased (Fig. 3c),
as the data in Fig. 3b (lower panels) show.
Our results suggest a dynamic trend, with a time-dependent
switch of circulating DP T-cell subsets in N3-ICtg blood.
Propagation of Notch3+highCXCR4+highDP T-cells outside the
thymus may be a result of the abnormal increase within young
N3-ICtg thymus (Fig. 2a) and their enhanced SDF-1-
dependent migratory ability (Fig. 1d), possibly related to the
decreased expression of thymic SDF-1 (Fig. 1c), which may
justify the decreased retention inside the thymus.
The wave of Notch3+CXCR4+DP T-cells progressively
invades N3-ICtg BM
CXCR4 expression facilitates pathogenic T-cell trafficking
in the BM of murine Aplastic Anemia model [28]. More-
over, BM stroma producing SDF-1 and vascular endothelial
niche are necessary for leukemic cell maintenance in T-
ALL progression [25].
To analyze BM infiltration in our mouse model, we first
assessed the percentages of DP T-cells in BM of 3-week-old
WT (0.2% ± 0.1%) and N3-ICtg (0.6% ± 0.4%) mice (Fig.
4a). Essentially, Notch3+CXCR4+ DP T-cells were
undetectable.
With disease progression, a massive infiltration of N3-
ICtg BM was observed (Fig. 4a). Indeed, we assessed the
higher percentage of total DP T-cells in N3-ICtg BM at
Fig. 3 High Notch3+CXCR4+DP T-cells in circulating blood of N3-
ICtg mice. a CD4/CD8 flow-cytometry analysis of blood from WT (n
= 3) and N3-ICtg (n= 3) mice (3-week old). b Left: representative
plots of CD4+CD8+ circulating in 6–8 and 12–14-week-old WT (n=
4) and N3-ICtg (n= 4) blood; Right: Notch3+CXCR4+ within DP-
gated T-cells. The average percentages ± SD of three to four analyzed
animals are indicated. c Ratio of the percentages of Notch3+CXCR4+
as fold over Notch3−CXCR4+ in DP-gated cells in N3-ICtg mice. For
each corresponding age, at least four N3-ICtg mice were analyzed.
(*p<0.05; **p<0.01; ****p < 0.0001; ns, not significant; One-way
ANOVA-test). See also Figure S2
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6–8 weeks (31.3% ± 12.8%), and at 12–14 weeks of age
(34.4% ± 14.2%), as opposed to 3-week-old mice (0.6% ±
0.4%) (Fig. 4a). In contrast, as shown in Fig. 4a, DP cells
were never detected in WT BM at 6–8 and 12–14 weeks of
age (0.5% ± 0.2% and 0.4% ± 0.3%, respectively). Mean-
while, at different ages, a statistically significant increase of
the absolute number of total DP T-cells infiltrating N3-ICtg
BM was observed (Fig. 4b).
Notch3+CXCR4+ T-cells mostly compose the DP
population infiltrating the BM in 6–8-week old (61.4% ±
14.2%), with a steady level in 12–14-week-old (57.9% ±
15.4%) N3-ICtg mice (Fig. 4a). Given these high percen-
tages, we speculate that this population colonizes and easily
proliferates in the transgenic BM niche. Thus, we compared
the absolute numbers of Notch3−CXCR4+DP versus
Notch3+CXCR4+ DP cells, normalized to total DP T-cell
values (Fig. 4c). No difference between the two subsets in
3-week-old mice was observed, in agreement with data
shown in Fig. 3c. Conversely, Notch3+CXCR4+DP cell
number peaks at 6–8 weeks and remains unchanged in
12–14-week-old N3-ICtg mice (Fig. 4c).
Newly, our results highlight the homing and expansion
of Notch3+CXCR4+ DP-cells in N3-ICtg BM, during T-
ALL progression.
The association of CXCR4 expression to site-specific
metastasis, into BM [29, 30] of neuroblastoma-bearing
patients [31], and the supportive effect of endothelial niche
in Notch-dependent T-ALL cells maintenance [25, 24],
favor our hypothesis that Notch3/CXCR4 crosstalk directs
“pre-leukemic” DP-cells to the BM.
High Notch3/CXCR4 co-expression facilitates DP
thymocytes homing and engraftment into BM
The “bone marrow-derived” leukemic cells, CXCR4-
dependent invaders [25, 24], T lymphoid precursors clo-
nal proliferation, and the suggested intrathymic origin of T-
ALL [32, 33] prompted us to analyze whether the Notch3
Fig. 4 Notch3+CXCR4+DP T-cells increasingly infiltrate N3-ICtg BM
with disease progression. In a, 3 weeks, 6–8 weeks, and 12–14 weeks
of age WT (n= 4) and N3-ICtg (n= 6) BM. On the left of each figure
section: representative plots of T-cell subset distribution. On the right:
Notch3+CXCR4+ co-expression within DP-gated T-cells. The average
percentages ± SD are shown. (**p<0.01; ns, not significant). b Abso-
lute numbers of DP cells infiltrating transgenic (n= 3) BM (*p < 0.05,
one-way ANOVA test). c Absolute numbers of Notch3+CXCR4+ and/
or Notch3−CXCR4+DP-cells normalized to total DP gated cells of N3-
ICtg bone marrow. For each corresponding age, at least five N3-ICtg
mice were used. One-way ANOVA (Tukey’s post-test) and Student’s
t-test performed where appropriate (**p < 0.01; ****p < 0.0001; ns,
not significant)
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+CXCR4+DP thymocytes, with high capability to migrate
and circulate in N3-ICtg mice, could specifically engraft
and infiltrate into BM of NSG recipient mice. In Figure
S3A, our separation protocol is schematized.
Purified CD4+CD8+ thymocytes of 6–8-week-old
transgenic mice, immunophenotypically distinguished in
Notch3+highCXCR4+high (N3high) or Notch3+lowCXCR4+high
(N3low) (Figure S3B) were injected intravenously (i.v.) into
NSG recipient mice. At day10 post-injection, BM cells from
mice receiving N3high cells, show a high percentage of
donor DP T-cells (6.95%), mostly composed of CD4+CD8
+Notch3+highCXCR4+high cells (89.7%) (Fig. 5a, upper
panels). Conversely, BM cells from N3low-injected mice
display only 0.1% of DP T-cells, essentially devoid of
surface Notch3 (Fig. 5a, lower panels). The evaluation of
DP T-cell numbers in BM of N3high-injected mice (Fig. 5b)
evidences their trend to greatly increase, by comparing DP
cell numbers at day1 and day10 (upper graph). Already at
day1, DP T-cell number is higher in N3high-injected when
compared to N3low-injected mice. In fact, at day1, N3lowDP
cells fail to home in NSG BM (Fig. 5b). Strikingly at day10,
we demonstrate that N3highDP cells achieve a greatly
increased engraftment in the BM of NSG recipient mice
when compared to N3lowDP cells (Fig. 5b). The difference
is clearly indicated by the increased ratio of DP cell num-
bers (Fig. 5b, lower graph) from N3high-injected versus
N3low-injected mice at day10. This evidence confirms the
higher competence of N3high thymocytes to home already at
Fig. 5 Selective homing and engraftment of N3-ICtg DP thymocytes,
highly expressing Notch3 and CXCR4. a (CD4+CD8+Notch3
+highCXCR4+high) N3high or (CD4+CD8+Notch3+lowCXCR4+high)
N3low thymocytes engraft in BM day10 post-intravenous injection
(i.v.). Percentages of DP cells (middle) and of CD4+CD8+Notch3
+CXCR4+ (right). b Absolute numbers of DP infiltrating NSG BM
after N3high (purple-circle) or N3low (blue-square) thymocytes i.v.
(upper, Kruskal–Wallis test) and the ratio N3high/N3lowDP cells at day1
(green-hexagon) and day10 (red-triangle) (lower, Mann–Whitney test)
(*p<0.05). c Ex vivo experiments: percentages of AnnexinV+cells in
N3high (upper) and N3low (lower) thymocytes in 24 h SDF-1-treated
relative to saline (PBS). Data are represented as meanvalue ± SD (**p
< 0.01; ns, not significant; Student’s t-test). d Absolute DP T-cell
numbers in spleen after N3high (purple-circle) or N3low (blue-square)
DP thymocytes i.v. (upper) and the ratio of N3high/N3lowDP T-cells
(lower) at day1 (green-hexagon) and day10 (red-triangle) (*p<0.05;
Student’s t-test, Mann–Whitney). See also Figure S3A and B
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day1 and to engraft and expand in the BM of recipient mice
10 days post-injection. This “fitness” may rely on the
enhanced responsivity of N3high cells to BM micro-
environment, releasing the pro-survival factor SDF-1. To
this regard, in ex vivo experiments, 24 h after SDF-1
treatment, we observed a significant reduction of sponta-
neous apoptosis, as measured by AnnexinV staining
(AnnnexinV+) within N3highDP thymocytes subset (Fig. 5c,
upper panel), when compared to N3lowDP cells, which
appear quite SDF-1 unresponsive (Fig. 5c, lower panel). We
hypothesize that Notch3 hyperexpression, through the
increased surface expression of CXCR4 (Fig. 1a), allows a
better DP settlement by potentiating SDF-1 responsiveness
and hence CXCR4-mediated survival programs. Interest-
ingly, N3high and N3lowDP cells have a different prolifera-
tion rate. In vivo BrdU labeling demonstrates that N3highDP
cells have an enhanced proliferation rate (Figure S4A and
B). Additionally, in comparison to N3low, N3highDP subset
displays a higher Ki67 expression as confirmed by higher
Ki67 MFI (Figure S4C).
Propagation of purified thymocytes was further analyzed in
the spleen. By day1 post-injection, N3highDP-cells invade the
spleen, further increasing at day10. In contrast, N3low cells are
nearly absent at both times (Fig. 5d, upper graph). Accord-
ingly, the ratio of Notch3+highCXCR4+high versus Notch3
+lowCXCR4+high (N3high/N3low) DP cells increases, sustaining
the competence of N3high to be successful in infiltrating both
BM and spleen (Fig. 5d, lower graph). Overall, we hypo-
thesize that Notch3/CXCR4 crosstalk enhances the early
spreading of N3highDP thymocytes toward BM and the spleen
in response to SDF-1 chemoattraction, thus evidentiating their
“fitness” in dissemination and expansion.
CXCR4 in vivo pharmacological antagonism reduces
BM infiltration by Notch3 overexpressing DP T-cells
AMD3100 is an extremely specific and effective CXCR4
antagonist. It has been used for hematopoietic stem cell
mobilization as well as for the treatment of myeloid leu-
kemia and solid tumors [34].
To investigate the effect of CXCR4 antagonism in
abnormal Notch3+CXCR4+DP cell propagation, we per-
formed a daily in vivo intraperitoneal (IP) administration of
young N3-ICtg mice, just before BM colonization occurs.
After 10 days, we evaluated DP T-cell numbers in BM by
flow cytometry, as shown in Fig. 6. Total DP cells that
infiltrate BM are greatly reduced by the administration of
AMD3100, as compared to PBS-injected mice (Fig. 6a).
Interestingly, infiltrating DP cells are mostly composed by
Notch3+CXCR4+, still significantly decreased in
AMD3100-treated with respect to PBS-injected mice (Fig.
6b). Notably, these results demonstrate that in vivo CXCR4
pharmacological antagonism can dramatically reduce the
BM infiltration and engraftment by “pre-leukemic” DP
cells. Therefore, this in vivo treatment may have significant
implications for a potential therapeutic approach.
Notch3 targets CXCR4 surface expression by
modulating β-arrestin1 function
For a molecular insight in Notch3-boosted CXCR4
expression, we modulated Notch3 function in a human
leukemia cell-line, TALL-1 cells, characterized by CD4/
CD8/CD3 expression, Notch3 activating mutations without
known alterations of Notch1 [4], and here, for the first time,
by high CXCR4 cell-surface expression (Fig. 7a).
We silenced the Notch3 gene in TALL-1 cells
(shNotch3) and hence we monitored CXCR4 cell-surface
expression by flow-cytometry, (Fig. 7a and S5).
Notch3 silencing impairs surface expression of CXCR4
(Fig. 7a, right panel), which is not accounted for by reduced
CXCR4 total protein levels (Figure S6A). In keeping with
unchanged CXCR4 mRNA levels in N3-ICtg with respect
to WT DP-cells (Fig. 1b), no Notch-induced transcriptional
regulation of CXCR4 mRNA has been reported in T-ALL1
cells [35]. Notably, silencing of Notch3 decreases CXCR4
Fig. 6 In vivo CXCR4
antagonism greatly contrast
atypical DP infiltration in N3-
ICtg BM. Three- to four-week-
old N3-ICtg mice were treated
daily with PBS (PBS) or with
the CXCR4 antagonist,
AMD3100. At day10 post-
injection, absolute numbers a of
DP T-cells and b of Notch3
+CXCR4+DP T-cells were
analyzed. PBS, n= 3;
AMD3100, n= 6. Results
represent mean ± SD (*p < 0.05;
**p < 0.01; Student’s t-test)
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cell-surface expression, while greatly impairing TALL-1
in vitro migration in response to SDF-1 (Fig. 7b).
CXCR4 internalization [36, 37] implies β-arrestin1
activity, whose Erk-triggered inhibitory control regulates β-
adrenergic receptor internalization [38]. Phosphorylation/
dephosphorylation at Ser-412 selectively regulates endo-
cytic but not desensitization function of β-arrestin [38].
With respect to control (CTRL), shNotch3 cells display a
reduced expression level of Ser-412-phosphorylated β-
arrestin1 (p-β-arrestin1), with respect to its unpho-
sphorylated form (Fig. 7c, left panel). This is in agreement
with decreased phospho/unphospho β-arrestin1 ratio (Figure
S6B). Together, these results correlate with decreased
phospho-Erk kinase in Notch3-silenced cells (Figure S6C),
and are in agreement with the Erk signaling enhancement
reported in DP/CD8+ thymocytes from N3-ICtg mice [39,
40]. In keeping with and supporting the above observations,
the whole-cell protein extracts (WCE) of thymocytes from
Fig. 7 β-arrestin1-mediated CXCR4 cell-surface modulation by
Notch3 in human leukemic cells. a Left: western blot analysis of
Notch3 protein. Right: flow-cytometry of CXCR4 cell-surface
expression in scrambled (CTRL) versus specific Notch3 silenced
(shNotch3) TALL-1 cells. b Transwell migration assay of CTRL and
shNotch3 cells in response to SDF-1 (5–50 ng/ml) (****p < 0.0001;
***p < 0.001, Student’s t-test). c Immunoblot assay of whole-cell
extract (WCE) of CTRL and shNotch3 cells (left), and thymocytes
from WT (WT1,2) and N3-ICtg (N3-ICtg1,2) mice (right). Phos-
phorylated (p-β-arrestin1) and unphosphorylated (β-arrestin1) β-
arrestin1 protein levels. d Flow-cytometry analysis of CXCR4
expression of Hek293 transiently transfected with N3-IC (0.7 μg)
either in the presence (1.4 μg) of β-arrestin1-wt (wt) or of the mutant
S412D (β-arrestin1-S412D). Right panel CXCR4 MFI of at least five
experiments (*p < 0.05, Student’s t-test). e Fractionated extract
(Nucleus, Cytoplasm) of CTRL and shNotch3 TALL-1 cells and from
DP/CD8+ thymocytes of WT and N3-ICtg 6–8-week-old mice. See
also Figure S4 and S6. f Optical densitometry of β-arrestin1 protein in
WT (n= 3) and N3-ICtg (n= 3) thymocytes (**p < 0.01, Student’s t-
test). Densitometry was performed on scanned immunoblot images
using ImageJ
Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation
6–8-week-old N3-ICtg mice (N3-ICtg1,2) display a higher
level of p-β-arrestin1, when compared to thymocytes from
WT mice (Fig. 7c, right panels).
To investigate the role of β-arrestin1 in mediating the
Notch3 effect on CXCR4 expression, we utilized a β-
arrestin1 mutant that mimics its phosphorylated form
Ser412→Asp (S412D) and acts as a dominant negative
inhibitor of receptor sequestration/internalization [41]. To
this purpose, we transiently cotransfected Hek293 cells with
the active Notch3-IC together with either the WT (β-
arrestin1-wt) or the phosphorylated mutant (β-arrestin1-
S412D) (Figure S7). As shown in Fig. 7d, we observed that,
in the presence of activated Notch3, the constitutively
phosphorylated form of β-arrestin1 (β-arrestin1-S412D)
enhances CXCR4 surface expression more efficiently with
respect to the wt form.
Together, the above results demonstrate that Notch3 is
able to sustain the levels of p-β-arrestin1, which in turn
cooperates with Notch3 to maintain the levels of
CXCR4 surface expression.
Notably, Notch3 silencing (shNotch3) reduces β-
arrestin1 in nuclear extract relative to CTRL cells (Fig. 7e,
left panels). Indeed, DP/CD8+ thymocyte fractionated
extracts reveal that β-arrestin1 protein increases in the
nucleus, but decreases in the cytoplasm of N3-ICtg mice
(Fig. 7e, right panels; and Figure S8A and B) supporting its
inability to internalize CXCR4.
Newly, our results correlate Notch3 hyperexpression to
altered β-arrestin1 function/localization, which impairs
CXCR4 internalization.
Finally, since we observed a significant decrease of β-
arrestin1 protein levels in thymocytes from N3-ICtg when
compared to WT mice (Fig. 7f), which would further sup-
port its role in regulating CXCR4 expression, in order to
investigate a possible translational significance of the cor-
relation between the CXCR4 receptor and the β-arrestin1
adaptor/scaffold protein, we performed an in silico analysis
of CXCR4 and β-arrestin1 gene expression in a cohort of
117 T-ALL pediatric patients [42]. Interestingly, we found a
significant inverse correlation between CXCR4 and β-
arrestin1 gene expression in selected patient subgroups
(Figure S9A and B).
Discussion
We characterized the impact of the relative “fitness” of
thymus-derived “pre-leukemic” DP-cells on BM homing
and engraftment. Still poorly understood are clues on what
goes astray when in a normal thymus originates T-cell
leukemia.
Gene expression profiling of human T-ALL samples,
distinguishes different stages of arrest during T-cell
development: (i) early immature T-ALLs at the DN stage,
opposed to (ii) CD1a+/CD4+/CD8+ or CD3+/CD4+/CD8+
T-cells, respectively, in early-cortical and late-cortical thy-
mocyte T-ALLs [43]. We report here the competitive pro-
gressive expansion of CD4+CD8+Notch3+highCXCR4+high
thymocytes in 3-week-old N3-ICtg thymus, peaking at
6–8 weeks and reaching a plateau at 12–14 weeks, well
correlated to the anomalous propagation of DP-cells in cir-
culating blood. Enhanced CXCR4 cell-surface expression
characterizes highly migrating transgenic DP thymocytes
and may interfere with normal T-cell/stroma interactions,
thus relieving Notch3+highCXCR4+highDP cells from outside
control. Our data converge on a “thymus-autonomous”
mechanism also relying on reduced SDF-1-dependent
retention inside the thymus of transgenic as opposed to
WT intrathymic microenvironment. Hence, early detection
of Notch3+highCXCR4+highDP in blood and BM of N3-ICtg
mice at 6–8 weeks of age may suggest DP accelerated egress
and thymus depletion, possibly unbalancing thymocyte sub-
populations. As a possible consequence of this, T-cell
depletion and subverted architecture in 12–14-week-old N3-
ICtg thymus occur as previously reported [18]. Our results
demonstrate the transient presence of Notch3+highCXCR4
+highDP in circulating blood, like a wave of early propa-
gating cells, further suggesting that Notch3+highCXCR4+high
expression is a possible “tag” to precociously detect abnor-
mally circulating DP-cells. In contrast, 12–14-week-old N3-
ICtg BM is still largely populated by Notch3+highCXCR4
+high DP-cells, suggesting that Notch3 makes them more fit
to BM colonization. Indeed, SDF-1-producing vascular
endothelial cells required in T-ALL niche [25] represents a
supportive microenvironment, chemoattracting and favoring
the expansion of Notch3+highCXCR4+highDP cells in BM
vascular niches.
We demonstrate that Notch3 modulates surface expres-
sion of CXCR4 in human TALL-1, by requiring β-arrestin1,
whose unphosphorylated status is necessary for β-arrestin/
src and β-arrestin/clathrin interaction and GPCR/CXCR4
receptor endocytosis [44, 45]. Intriguingly, the β-arrestin1-
S412D mutant, unable to bind clathrin and acting as a
dominant negative inhibitor of receptor sequestration/inter-
nalization [41], enhances Notch3-induced CXCR4 cell-
surface expression. We observed here that in N3-ICtg DP
thymocytes, β-arrestin1 undergoes heavy Ser412-
phosphorylation and increased nuclear translocation, sug-
gesting the impairment of its function toward CXCR4
internalization. Additionally to previous data [24] linking
CXCR4 recycling to calcineurin-dependent expression of
cortactin, we propose that Notch3 regulates function and
expression of β-arrestin1 to prevent CXCR4 receptor
internalization. Nevertheless, β-arrestin1 can bind and
colocalize with cortactin [46], and we cannot exclude their
convergent connection.
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To go further beyond the Notch3+highCXCR4+highDP
organ-wide dissemination, we investigated their migratory
ability in in vivo NSG transplant experiments. Our results
highlight that not simply DP, but selected N3highDP thy-
mocytes are efficient in positioning into BM, already at
day1 post-injection. We report here for the first time how a
wave of “thymus-derived” Notch3+highCXCR4+highDP-cells
is able to home and engraft into BM of NSG recipient mice,
while the ability of “bone marrow-derived” leukemic cells
to infiltrate lymphoid organs and CNS in T-ALL was pre-
viously reported [24, 25, 47]. We show that high CXCR4 is
per se insufficient, but requires an active Notch stimulus,
Notch3 in our model, that possibly potentiates the SDF-1-
driven nest of Notch3+highCXCR4+highDP-cells into BM
niches. Our results delineate a new mechanism by which a
specific subset of DP T-cells, with a high Notch3 and
CXCR4 co-expression and an elevated proliferation rate,
are forced to egress from the thymus and fit to rapidly
colonize BM and possibly peripheral organs (i.e., the
spleen) during T-ALL progression.
In support of our hypothesis, in vivo CXCR4 antagonism
by AMD3100 can contrast atypical DP infiltration in the
BM of young N3-ICtg mice. Notably, the increased number
of N3high and the ratio N3high/N3low DP cells infiltrating the
spleen further highlight the environmental requirements to
sustain Notch3+highCXCR4+highDP “fitness” in T-cell leu-
kemia propagation. It has been previously shown that pri-
mary explants of T-ALL are prone to apoptosis unless
stromal stimuli, like Notch ligands (Delta-like1) and SDF-1,
are present [25, 48]. In keeping with this we observed a
reduced spontaneous apoptosis in SDF-1-treated N3highDP-
cells, while apoptosis of N3low DP-cells resulted unaffected
by SDF-1 treatment. The incompetence of N3lowDP T-cells
to home and engraft into BM and spleen, at day1 and day10
post-injection, underlies the need of a strong Notch signal
for committing CXCR4-expressing leukemic cells to pro-
pagate and expand in peripheral organs.
In conclusion, our results highlight a new perspective
function of CXCR4 combined with Notch3 in selecting and
mobilizing “pre-leukemic” DP cells that easily fit to dis-
seminate in early T-ALL progression. Moreover, the
Notch3/CXCR4 crosstalk suggests the attractive possibility
of combined therapy protocols to precociously target T-
ALL cells.
Materials and methods
Mice
N3-ICtg mice [18] were bred and maintained as reported in
[49]. NOD.Cg-Prkdcscid (NSG) immune-compromised
recipient mice (Charles-River Laboratories). Animal
experiments performed with at least three animals of each
genotype. The number of used mice is reported in each
Figure legend. Experimental mice groups were based on age
and genotype. No mice were excluded during the experi-
ments. All animal experiments were performed according to
Italian D.Lgs. n.26/2014 and European Directive 2010/63/
UE.
Cell culture
Hek293T, TALL-1 cells were maintained as described
elsewhere [4, 50] and all are mycoplasma-free.
Cell transfections and plasmids
Hek293 cells were transiently transfected by TransFec-
tin™Lipid Reagent (BioRad) as in [51]. Expression plas-
mids used: pCMV-Notch3-IC-HA [18], pcDNA3-βarr1-
HA, and pcDNA3-βarr1-S412D-Flag [41] (gift from Robert
Lefkowitz; Addgene plasmid #42196).
siRNA silencing experiments
TALL-1 cells were transfected with 200 nM siRNAs anti-
Notch3 (Santa-Cruz, sc-37135) or (Dharmacon, s1623) and
their corresponding control scrambled siRNAs (Santa-Cruz,
sc-37007 and Dharmacon, D-001810-10-20) using Neon
transfection System (Invitrogen) following manufacturer’s
recommendations. Ninety-six hours post-transfection,
TALL-1 cells were stained with anti-CXCR4 (BD-Bios-
ciences, 560936) or IgM isotype (eBioscience, 17-4341),
and analyzed in FACSCalibur with CellQuest software
(BD-Biosciences).
RT-PCR/qRT-PCR
Total RNA extraction and reverse transcription-polymerase
chain reaction (RT-PCR) were described [52]. CXCR4 and
HPRT mRNA levels were determined by TaqMan quanti-
tative real-time RT-PCR (qRT-PCR) performed on cDNA
following manufacturer’s instructions (Applied-Biosys-
tems). Data analysis by ΔΔCt method (HPRT use for nor-
malization of mRNA levels).
Migration assay
In vitro SDF-1-induced (Peprotech) migration was per-
formed with thymocytes (20 and 200 ng/ml) or TALL-1
cells (5 and 50 ng/ml) as described in [53]. An unrelated
ligand, SLC (1 μg/ml; Protech) was used. Ninety minutes
post-induction, cell-migration was counted by FACS as in
[54].
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Protein extracts and immunoblotting
Nuclear-cytosol fractionations of purified DP/CD8+ cells,
with CD8a(Ly-2) microbeads (Miltenyi-Biotec) following
manufacturer’s protocol, and of TALL-1 cells were per-
formed as described [23, 55].
WCE and immunoblotting assays were performed as
described [23]. Used antibodies: Anti-Flag(F3165), anti-β-
actin(A5441) (Sigma-Aldrich); anti-Phospho-β-arrestin1-
Ser412(2416), anti-Notch3(2889) (Cell-Signaling); anti-β-
arrestin-1(sc-9182), anti-Phospho-Erk(sc-7383), anti-Erk-1/
2(sc-93/sc-154), anti-α-tubulin(sc-803) and anti-LaminB
(sc6217) (Santa-Cruz); Anti-CXCR4 (ABCAM; 2074).
Flow cytometry
T-cells from thymi, blood, and BM were processed as
described [22] and stained with anti-CD4-PerCP-Cy5.5,
anti-CD8-APC, IgG2bPE(12-4031) (BD-Biosciences); anti-
CXCR4-PE (eBioscience); anti-Notch3-Fitch(AF1308) and
normal goat-IgG(AB-108-C) (R&D Systems) [53]. Samples
analysis on FACSCalibur using CellQuest-software (BD-
Biosciences).
CD8-H7(560182) was used with anti-AnnexinV-APC
(550474) (BD-Biosciences). FACSCantoII (Becton-Dick-
inson) analysis with DivaVersion6.1.3 or
FlowJoVersion8.5.2 software was performed. Blinded-
conducted analysis performed.
Cell sorting for in vivo cell transfer experiment
Thymocytes of 8-week-old N3-ICtg mice were stained with
antibodies abovementioned in flow cytometry.
For in vivo cell transfer experiment, CD4+CD8+Notch3
+highCXCR4+high (N3high) and CD4+CD8+Notch3
+lowCXCR4+high (N3low) thymocytes of N3-ICtg mice were
isolated (purity level > 90%) by FACSAria cell-sorter (BD
Biosciences) [56].
2.5 × 106 purified (N3+high) or (N3+low) DP T-cells were
i.v. injected in NSG mice.
At day1 and day10 post-injection, 2 × 106 cells from
spleen and BM of NSG recipient mice were stained as
above-mentioned in flow cytometry. FACSCantoII (Becton-
Dickinson) analysis with DivaVersion6.1.3 or
FlowJoVersion8.5.2 software was performed.
In vivo administration of AMD3100
Three- to four-week-old N3-ICtg mice were IP injected
daily with AMD3100 (10 mg/kg; Sigma-Aldrich) or vehicle
(PBS). FACS analysis of BM cells was performed at day1
and day10. Antibodies are mentioned above in flow cyto-
metry [53].
Statistical analysis
Comparison of two groups using unpaired t-test or
Mann–Whitney test was done. Comparison of more groups
using one-way ANOVA (Tukey’s post-test and
Kruskal–Wallis test) was done. A p-value of <0.05 was
considered as statistically significant (*p < 0.05, **p< 0.01,
***p < 0.001, ****P < 0.0001; §§p < 0.01; §§§§p < 0.0001).
At least three independent experiments are reported as
mean ± SD (the repeat number was increased according to
effect size or sample variation). Estimation of sample’s size
considering variation and mean of samples was done. No
statistical method was used to predetermine sample size. No
animals/samples were excluded from the analysis. Statis-
tical analysis was conducted with PRISM-program
(GraphPad).
In vivo BrdU labeling and Ki67 staining
Each 8-week-old N3-ICtg mouse was IP injected with
1.5 mg/150 ml BrdU (Sigma-Aldrich; B9285) in PBS; 24 h
post-IP-injection, anti-CD4/anti-CD8/anti-Notch3 extra-
cellular staining was followed either by anti-BrdU (BioLe-
gend; 339807) [57] or fixed and permeabilized for
intracellular antigen detection of BV510mouse Aati-Ki-67
(BD-563462).
In silico analysis of T-ALL patients’ deposited data
Blood samples from 117 pediatric T-ALL patients [42] were
selected and analyzed for correlation between CXCR4 and
ARRB1. Expression probe sets 217028_at representing
CXCR4 and 222912_at representing ARRB1 were used.
Acknowledgements Dedicated to Alberto Gulino. We thank Maria
Pelullo, Giulia Diluvio, and Rebeka Popovic for skillful assistance in
experiments, Mr. Alessandro Martini for mouse husbandry and Mr.
Fernando Duranti for technical assistance, and Sarah Sturman for help
in editing the manuscript. Funding was provided by Sapienza Uni-
versity, Ateneo 2015 (C26A15MHEL), and Ateneo 2016
(RP116154CE3A9FA1) to MPF.
Author contributions FF and GT designed and performed the
research, analyzed the data and wrote the draft; GB performed the
research and analyzed the data; AFC and PG performed the animal
experiments and cell sorting; CN and AC performed the animal
experiments; ZMB performed in silico analysis; AV and DB per-
formed the transfection experiments; IS designed the research, ana-
lyzed the data and wrote the manuscript, MPF designed and performed
the research, analyzed the data and wrote the manuscript.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
F. Ferrandino et al.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB,
Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in
human T cell acute lymphoblastic leukemia. Science.
2004;306:269–71.
2. Bellavia D, Campese AF, Checquolo S, Balestri A, Biondi A,
Cazzaniga G, et al. Combined expression of pTα and Notch3 in T
cell leukemia identifies the requirement of preTCR for leukemo-
genesis. Proc Natl Acad Sci USA. 2002;99:3788–93.
3. Campese AF, Bellavia D, Gulino A, Screpanti I. Notch signalling
at the crossroads of T cell development and leukemogenesis.
Semin Cell Dev Biol. 2003;14:151–7.
4. Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth
E, et al. Characterization of activating mutations of NOTCH3 in T
cell acute lymphoblastic leukemia and anti-leukemic activity of
NOTCH3 inhibitory antibodies. Oncogene. 2016;35:6077–86.
5. Washburn T, Schweighoffer E, Gridley T, Chang D, Fowlkes B,
Cado D, et al. Notch activity influences the αβ versus γδ T cell
lineage decision. Cell. 1997;88:833–43.
6. Felli MP, Maroder M, Mitsiadis TA, Campese AF, Bellavia D,
Vacca A, et al. Expression pattern of Notch1, 2 and 3 and Jagged1
and 2 in lymphoid and stromal thymus components: distinct
ligand–receptor interactions in intrathymic T cell development. Int
Immunol. 1999;11:1017–25.
7. Martins VC, Busch K, Juraeva D, Blum C, Ludwig C, Rasche V,
et al. Cell competition is a tumour suppressor mechanism in the
thymus. Nature. 2014;509:465–70.
8. Chatterjee S, Azad BB, Nimmagadda S. The intricate role of
CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82.
9. Petrie HT, Zúñiga-Pflücker JC. Zoned out: functional mapping of
stromal signaling microenvironments in the thymus. Annu Rev
Immunol. 2007;25:649–79.
10. Poznansky MC, Olszak IT, Foxall R, Evans RH, Luster AD,
Scadden DT. Active movement of T cells away from a chemo-
kine. Nat Med. 2000;6:543–8.
11. Cyster JG. Chemorepulsion and thymocyte emigration. J Clin
Investig. 2002;109:1011–2.
12. Ara T, Itoi M, Kawabata K, Egawa T, Tokoyoda K, Sugiyama T,
et al. A role of CXC chemokine ligand 12/stromal cell-derived
factor-1/pre-B cell growth stimulating factor and its receptor
CXCR4 in fetal and adult T cell development in vivo. J Immunol.
2003;170:4649–55.
13. Plotkin J, Prockop SE, Lepique A, Petrie HT. Critical role for
CXCR4 signaling in progenitor localization and T cell differ-
entiation in the postnatal thymus. J Immunol. 2003;171:4521–7.
14. Janas ML, Varano G, Gudmundsson K, Noda M, Nagasawa T,
Turner M. Thymic development beyond β-selection requires
phosphatidylinositol 3-kinase activation by CXCR4. J Exp Med.
2010;207:247–61.
15. Trampont PC, Tosello-Trampont A-C, Shen Y, Duley AK,
Sutherland AE, Bender TP, et al. CXCR4 acts as a costimulator
during thymic [beta]-selection. Nat Immunol. 2010;11:162–70.
16. Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of
innate and adaptive immunity by Notch. Nat Rev Immunol.
2013;13:427–37.
17. Janas ML, Turner M. Stromal cell-derived factor 1α and CXCR4:
newly defined requirements for efficient thymic β-selection.
Trends Immunol. 2010;31:370–6.
18. Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, Balestri
A, et al. Constitutive activation of NF‐κB and T‐cell leukemia/
lymphoma in Notch3 transgenic mice. EMBO J.
2000;19:3337–48.
19. Bellavia D, Mecarozzi M, Campese AF, Grazioli P, Talora C,
Frati L, et al. Notch3 and the Notch3‐upregulated RNA‐binding
protein HuD regulate Ikaros alternative splicing. EMBO J.
2007;26:1670–80.
20. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J,
et al. Exclusive development of T cell neoplasms in mice trans-
planted with bone marrow expressing activated Notch alleles. J
Exp Med. 1996;183:2283–91.
21. Franciosa G, Diluvio G, Del Gaudio F, Giuli M, Palermo R,
Grazioli P, et al. Prolyl-isomerase Pin1 controls Notch3 protein
expression and regulates T-ALL progression. Oncogene.
2016;35:4741–51.
22. Felli MP, Vacca A, Calce A, Bellavia D, Campese AF, Grillo R,
et al. PKC [theta] mediates pre-TCR signaling and contributes to
Notch3-induced T-cell leukemia. Oncogene. 2005;24:992.
23. Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine
M, et al. Notch3 and pre‐TCR interaction unveils distinct NF‐κB
pathways in T‐cell development and leukemia. EMBO J.
2006;25:1000–8.
24. Passaro D, Irigoyen M, Catherinet C, Gachet S, De Jesus CDC,
Lasgi C, et al. CXCR4 is required for leukemia-initiating cell
activity in T cell acute lymphoblastic leukemia. Cancer Cell.
2015;27:769–79.
25. Pitt LA, Tikhonova AN, Hu H, Trimarchi T, King B, Gong Y,
et al. CXCL12-producing vascular endothelial niches control
acute T cell leukemia maintenance. Cancer Cell. 2015;27:755–68.
26. Halkias J, Melichar HJ, Taylor KT, Ross JO, Yen B, Cooper SB,
et al. Opposing chemokine gradients control human thymocyte
migration in situ. J Clin Investig. 2013;123:2131–42.
27. Campese AF, Garbe AI, Zhang F, Grassi F, Screpanti I, Von
Boehmer H. Notch1-dependent lymphomagenesis is assisted by
but does not essentially require pre-TCR signaling. Blood.
2006;108:305–10.
28. Kuksin CA, Gonzalez-Perez G, Minter LM. CXCR4 expression
on pathogenic T cells facilitates their bone marrow infiltration in a
mouse model of aplastic anemia. Blood. 2015;125:2087–94.
29. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G,
Witz IP, et al. A possible role for CXCR4 and its ligand, the CXC
chemokine stromal cell-derived factor-1, in the development of
bone marrow metastases in neuroblastoma. J Immunol.
2001;167:4747–57.
30. Ben-Baruch A. Site-specific metastasis formation: chemokines as
regulators of tumor cell adhesion, motility and invasion. Cell Adh
Migr. 2009;3:328–33.
31. Russell HV, Hicks J, Okcu MF, Nuchtern JG. CXCR4 expression
in neuroblastoma primary tumors is associated with clinical pre-
sentation of bone and bone marrow metastases. J Pediatr Surg.
2004;39:1506–11.
32. Scupoli MT, Donadelli M, Cioffi F, Rossi M, Perbellini O, Mal-
peli G, et al. Bone marrow stromal cells and the upregulation of
interleukin-8 production in human T-cell acute lymphoblastic
leukemia through the CXCL12/CXCR4 axis and the NF-κB and
JNK/AP-1 pathways. Haematologica. 2008;93:524–32.
Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation
33. Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema
NA, et al. Biology and treatment of childhood T-lineage acute
lymphoblastic leukemia. Blood. 1998;91:735–46.
34. Liu T, Li X, You S, Bhuyan SS, Dong L. Effectiveness of
AMD3100 in treatment of leukemia and solid tumors: from ori-
ginal discovery to use in current clinical practice. Exp Hematol
Oncol. 2015;5:19.
35. Mirandola L, Chiriva‐Internati M, Montagna D, Locatelli F, Zecca
M, Ranzani M, et al. Notch1 regulates chemotaxis and prolifera-
tion by controlling the CC‐chemokine receptors 5 and 9 in T cell
acute lymphoblastic leukaemia. J Pathol. 2012;226:713–22.
36. Marchese A, Trejo J. Ubiquitin-dependent regulation of G protein-
coupled receptor trafficking and signaling. Cell Signal.
2013;25:707–16.
37. Puca L, Brou C. α-Arrestins–new players in Notch and GPCR
signaling pathways in mammals. J Cell Sci. 2014;127:1359–67.
38. Lin F-T, Miller WE, Luttrell LM, Lefkowitz RJ. Feedback reg-
ulation of β-arrestin1 function by extracellular signal-regulated
kinases. J Biol Chem. 1999;274:15971–4.
39. Talora C, Campese AF, Bellavia D, Pascucci M, Checquolo S,
Groppioni M, et al. Pre‐TCR‐triggered ERK signalling‐dependent
downregulation of E2A activity in Notch3‐induced T‐cell lym-
phoma. EMBO Rep. 2003;4:1067–71.
40. Talora C, Cialfi S, Oliviero C, Palermo R, Pascucci M, Frati L,
et al. Cross talk among Notch3, pre-TCR, and Tal1 in T-cell
development and leukemogenesis. Blood. 2006;107:3313–20.
41. Luttrell L, Ferguson S, Daaka Y, Miller W, Maudsley S, Della
Rocca G, et al. β-Arrestin-dependent formation of β2 adrenergic
receptor-Src protein kinase complexes. Science.
1999;283:655–61.
42. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A,
Verstegen M, et al. Integrated transcript and genome analyses
reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute
lymphoblastic leukemia. Cancer Cell. 2011;19:484–97.
43. Van Vlierberghe P, Ferrando A. The molecular basis of T cell
acute lymphoblastic leukemia. J Clin Investig. 2012;122:3398.
44. Lin F-T, Krueger KM, Kendall HE, Daaka Y, Fredericks ZL,
Pitcher JA, et al. Clathrin-mediated endocytosis of the β-adre-
nergic receptor is regulated by phosphorylation/dephosphorylation
of β-arrestin1. J Biol Chem. 1997;272:31051–7.
45. Hupfeld CJ, Resnik JL, Ugi S, Olefsky JM. Insulin-induced β-
arrestin1 Ser-412 phosphorylation is a mechanism for desensiti-
zation of ERK activation by Gαi-coupled receptors. J Biol Chem.
2005;280:1016–23.
46. Goertzen CG, Dragan M, Turley E, Babwah AV, Bhattacharya M.
KISS1R signaling promotes invadopodia formation in human
breast cancer cell via β-arrestin2/ERK. Cell Signal.
2016;28:165–76.
47. Jost TR, Borga C, Radaelli E, Romagnani A, Perruzza L, Omodho
L, et al. Role of CXCR4-mediated bone marrow colonization in
CNS infiltration by T cell acute lymphoblastic leukemia. J Leukoc
Biol. 2016;99:1077–87.
48. Armstrong F, de la Grange PB, Gerby B, Rouyez M-C, Calvo J,
Fontenay M, et al. NOTCH is a key regulator of human T-cell
acute leukemia initiating cell activity. Blood. 2009;113:1730–40.
49. Barbarulo A, Grazioli P, Campese AF, Bellavia D, Di Mario G,
Pelullo M, et al. Notch3 and canonical NF-κB signaling pathways
cooperatively regulate Foxp3 transcription. J Immunol.
2011;186:6199–206.
50. Pelullo M, Quaranta R, Talora C, Checquolo S, Cialfi S, Felli MP,
et al. Notch3/Jagged1 circuitry reinforces notch signaling and
sustains T-ALL. Neoplasia. 2014;16:1007–17.
51. Massimi I, Ciuffetta A,Temperilli F, Ferrandino F, Zicari A, Pulci-
nelli FM, et al. Multidrug resistance protein-4 influences aspirin
toxicity in human cell line. Mediators Inflamm. 2015;2015:607957.
52. Quaranta R, Pelullo M, Zema S, Nardozza F, Checquolo S, Lauer
DM, et al. Maml1 acts cooperatively with Gli proteins to regulate
sonic hedgehog signaling pathway. Cell Death Dis. 2017;8:e2942.
53. Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S,
Santoni A. CCL3 and CXCL12 regulate trafficking of mouse bone
marrow NK cell subsets. Blood. 2008;111:3626–34.
54. Bernardini G, Kim JY, Gismondi A, Butcher EC, Santoni A.
Chemoattractant induces LFA-1 associated PI 3K activity and cell
migration that are dependent on Fyn signaling. FASEB J.
2005;19:1305–7.
55. Checquolo S, Palermo R, Cialfi S, Ferrara G, Oliviero C, Talora
C, et al. Differential subcellular localization regulates c-Cbl E3
ligase activity upon Notch3 protein in T-cell leukemia. Oncogene.
2010;29:1463.
56. Campese AF, Grazioli P, de Cesaris P, Riccioli A, Bellavia D,
Pelullo M, et al. Mouse Sertoli cells sustain de novo generation of
regulatory T cells by triggering the notch pathway through soluble
JAGGED1. Biol Reprod. 2014;90:51–10. 53
57. Parretta E, Cassese G, Santoni A, Guardiola J, Vecchio A, Di
Rosa F. Kinetics of in vivo proliferation and death of memory and
naive CD8 T cells: parameter estimation based on 5-bromo-2′-
deoxyuridine incorporation in spleen, lymph nodes, and bone
marrow. J Immunol. 2008;180:7230–9.
F. Ferrandino et al.
